AACR 2023: AEGEAN trial demonstrates improved OS for durvalumab NSCLC treatment arm

A recent Phase III placebo-controlled trial called AEGEAN saw patients with treatment-naïve NSCLC treated with neoadjuvant Imfinzi® (durvalumab), plus chemotherapy with further adjuvant durvalumab monotherapy, showing an increase in event-free survival (EFS) with complete pathological complete response (pCR) when compared to those treated with only neoadjuvant chemotherapy. The findings were recently presented at the AACR Annual Meeting 2023 (April 14−19 2023, FL, USA). The AEGEAN trial was a randomized, double blind, placebo-controlled trial with 802 treatment-naïve resectable NSCLC patients. These patients were randomly assigned (1:1),irrespective of PD-L1 expression, to receive durvalumab plus platinum-based chemotherapy with the durvalumab being either neoadjuvant...